NASDAQ · Medical - Devices

QTRX (QTRX) Stock

$3.38 -3.15% NASDAQ: QTRX Healthcare

Valuation

MetricValue
Price$3.38
Market Cap$159.22M
P/E Ratio-1.00
P/B Ratio0.40
P/S Ratio0.82
EPS (TTM)$-2.51
52-Week High$8.77
52-Week Low$2.40
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-36.15%
ROA-25.54%
ROCE-37.16%
Gross Margin-78.42%
Operating Margin-79.14%
Net Margin-71.92%
Debt/Equity0.13
Current Ratio2.83

Annual Financials (USD)

Metric20212022202320242025
Revenue$111.0M$106.0M$121.0M$135.0M$139.0M
Operating Profit$-57.0M$-104.0M$-46.0M$-53.0M$-110.0M
Net Profit$-56.0M$-100.0M$-28.0M$-39.0M$-107.0M
EPS$-1.60$-2.61$-0.86$-1.00$-2.51
Op Margin-51.1%-98.8%-38.0%-38.9%-79.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$507.0M$434.0M$429.0M$407.0M$419.0M
Total Liabilities$66.0M$76.0M$79.0M$76.0M$123.0M
Cash$396.0M$339.0M$174.0M$57.0M$30.0M
Borrowings$22.0M$44.0M$41.0M$37.0M$37.0M

Latest News

Quanterix Advances Adoption of LucentAD Complete Blood Test MT Newswires · Jul 14, 2026 Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages Business Wire · Jul 14, 2026 Quanterix (QTRX) Stock Fair Value Falls After Analysts Cut Price Targets Simply Wall St. · Jul 9, 2026 TRIB, QTRX, RCON: Why These Stocks Are Surging After-Hours Today Stocktwits · Jun 24, 2026 Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-48.0M$-48.0M$-19.0M$-35.0M$-77.0M
Investing Cash Flow$-20.0M$-23.0M$-152.0M$-86.0M$48.0M
Financing Cash Flow$9.0M$0$0$-3.0M$-1.0M
Net Cash Flow$216.0M$-58.0M$-164.0M$-118.0M$-26.0M
Free Cash Flow$-62.0M$-60.0M$-23.0M$-39.0M$-80.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-69.83%
Quick Ratio2.70
Interest Coverage—
Return 1Y-32.56%
Return 3Y-82.89%
Return 5Y-92.21%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CVRX $4.88 +2.95% -2.98 $129.50M 0.00%
IMRX $4.24 -2.75% -3.94 $153.92M 0.00%
INGN $6.49 +1.09% -8.00 $175.71M 0.00%
MASS $8.30 -1.31% 12.81 $340.53M 0.00%
NNOX $1.06 +3.92% -1.56 $73.78M 0.00%

About QTRX

QTRX is led by CEO Everett V. Cunningham, publicly traded since 2017.

QTRX stock trades at $3.38 with a market capitalization of $159.22M. The stock is valued at a price-to-earnings (P/E) ratio of -1.00, price-to-book of 0.40, price-to-sales of 0.82. Over the past 52 weeks the stock has ranged between $2.40 and $8.77, and currently trades 61.5% below its 52-week high.

On profitability, QTRX generates a return on equity (ROE) of -36.15%, return on capital employed of -37.16%, an operating margin of -79.14%, a net profit margin of -71.92%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides